CJC-1295 vs Sermorelin vs Ipamorelin: Growth Hormone Secretagogues Compared
Growth-hormone secretagogue research involves two distinct receptor systems that are constantly conflated. Sorting the three most studied compounds into their correct mechanistic boxes makes the entire literature easier to read.
Two receptors, two families
GHRH analogs — sermorelin and CJC-1295 — act on the GHRH receptor in the anterior pituitary, the same receptor the hypothalamus uses to trigger natural GH pulses. Ghrelin mimetics — ipamorelin — act on the entirely separate GHS-R1a receptor, which amplifies pulses and suppresses somatostatin (the brake on GH release). The two mechanisms are synergistic in published models, which is the entire rationale for pairing one of each.
The three compounds
| Sermorelin | CJC-1295 (no DAC) | Ipamorelin | |
|---|---|---|---|
| Class | GHRH analog — GRF(1-29) | Modified GRF(1-29), four substitutions | Ghrelin mimetic, pentapeptide |
| Receptor | GHRH-R | GHRH-R | GHS-R1a |
| Half-life (research literature) | ~10–20 minutes | ~30 minutes | ~2 hours |
| Selectivity notes | Mimics native GHRH closely | Substitutions resist DPP-4 cleavage — same pulse shape, longer action | Notably selective: published data show minimal cortisol, prolactin or appetite signal vs older mimetics like GHRP-6 |
| History | Formerly an approved pediatric diagnostic/therapeutic (Geref), later withdrawn commercially | Research compound only | Reached early clinical trials (postoperative ileus), discontinued |
Why pulsatility dominates this literature
GH physiology is pulsatile, and downstream signaling (IGF-1 induction, receptor sensitivity) depends on preserving that rhythm. This is why the short half-lives of GHRH analogs are treated as a feature in research design, and why the long-acting DAC version of CJC-1295 — which flattens pulses into continuous elevation — is studied as a deliberately different pharmacological question. Our catalogue stocks the no-DAC form, the pulse-preserving variant.
Pairing logic in research protocols
A GHRH analog initiates the pulse; a ghrelin mimetic amplifies it and lifts somatostatin suppression. Published rodent and human physiology work found the combination produces greater GH release than either alone at the same doses — hence the standard pairing in secretagogue research. The CJC-1295 + ipamorelin combination vial covers both arms with a single certificate; the compounds are also available separately: sermorelin, CJC-1295 no DAC, ipamorelin, and tesamorelin — the only GHRH analog in the group with current FDA approval (HIV-associated lipodystrophy) and the natural positive-control choice.
For research use only — not for human or veterinary use.